Antares Pharma, Inc. Announces Notice Of Allowance For New Patent On Reconstitutable Lyophilized Injectables

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received a Notice of Allowance from the U.S. Patent Office for application 13/584,317. This application, along with U.S. Patent 8,251,947 granted in August of 2012, relate to Antares’ injector technology for wet-dry injectable drugs such as lyophilized biologicals or peptide drugs that require dry storage to assure stability. The designs described in the application result in the injector performing the reconstitution of the dry drugs into an injectable liquid form and then perform the injection similar to the Antares VIBEX® and QuickShot™ devices. Adding the reconstitution mechanism to the base of the VIBEX® and QuickShot™ injection platform allows the Company to build on its comprehensive technology platform upon which OTREXUP™ was developed. The expiry date for the patent issued in August of 2012 is 2028.

Help employers find you! Check out all the jobs and post your resume.